Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Abstract
Summary null null Background null Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. null null null Methods null We...
Paper Details
Title
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
Published Date
Oct 1, 2019
Journal
Volume
20
Issue
10
Pages
1395 - 1408
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History